RxDoctor Payments Data

Sreeker Reddy, DO

Cardiovascular Disease · Sterling Heights, MINPI 1952782476

Payments from drug & device makers

$5,212in general payments, 2019–2025

Across 170 payments — averaging $30.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$587
  • Medtronic$443
  • Boston Scientific$416
  • E.r. Squibb & Sons, L.L.C.$253
  • Novartis$234
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$4,99196%
  • Education$2214%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,212 in reported general payments places this provider in the 55th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$235,398
Medicare patients
905
Services billed
2,240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$76,286
XareltoRivaroxaban12$13,374
BrilintaTicagrelor13$12,805
Repatha SureclickEvolocumab12$6,485
Metoprolol Succinate113$2,150
Atorvastatin Calcium67$1,440
Rosuvastatin Calcium34$989
Amlodipine Besylate67$500
Carvedilol40$449
Losartan Potassium47$436
Lisinopril38$297
Nitroglycerin12$296
ClopidogrelClopidogrel Bisulfate14$269
Furosemide30$209
Isosorbide Mononitrate ErIsosorbide Mononitrate11$155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$230$76,28656 claims
Johnson & JohnsonXarelto$85$13,37412 claims
AstraZenecaBrilinta$109$12,80513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Sterling Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →